

A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression

Reckweg JT, van Leeuwen CJ, Henquet C, van Amelsvoort T, Theunissen EL, Mason NL, Paci R, Terwey TH, Ramaekers JG.

Frontiers in psychiatry

2023; 14

ARTICLE IDENTIFIERS

DOI: 10.3389/fpsy.2023.1133414

PMID: unavailable

PMCID: not available

JOURNAL IDENTIFIERS

LCCN: not available

pISSN: not available

eISSN: 1664-0640

OCLC ID: not available

CONS ID: not available

US National Library of Medicine ID: 101545006

This article was identified from a query of the SafetyLit database.